U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Donahue KE, Gartlehner G, Schulman ER, et al. Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Jul. (Comparative Effectiveness Review, No. 211.)

Cover of Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update

Drug Therapy for Early Rheumatoid Arthritis: A Systematic Review Update [Internet].

Show details
Figure 25 displays a forest plot for the network meta-analysis reporting discontinuations due to adverse events in studies comparing MTX plus Non-TNF biologics with Non-TNF biologics alone. Two comparisons were used in this analysis. Study-level data used in this Figure are presented in Appendix C. This figure is described further in the KQ3 Results section “csDMARDs Versus Biologics” as follows: “NWMA also examined ABA plus MTX and found no significant differences in overall discontinuations but fewer discontinuations due to adverse events for ABA plus MTX than ABA monotherapy (RR, 0.34; 95% CI, 0.18 to 0.64)”.

Figure 25Forest plot for network meta-analysis of discontinuations due to adverse events: Non-TNF + MTX versus non-TNF

95% CI = 95% confidence interval; MTX = methotrexate; RR = relative risk; TNF = tumor necrosis factor; vs. = versus.

Views

  • Cite this Page
  • PDF version of this title (24M)

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...